Streetbeat News

Analyst Ratings

FSLY

Fastly's stock (FSLY) is experiencing an uptick following an upgrade from Citigroup, which changed its rating from Sell to Neutral and increased the price target from $11 to $20.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 1:58 pm

S

SentinelOne's stock is experiencing an uptick following an upgrade from Neutral to Buy by BTIG, which also set a price target of $30 for the company's shares.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 1:56 pm

BRSP

Barclays analyst Terry Ma has maintained an Equal-Weight rating on BrightSpire Capital (NYSE:BRSP) and increased the price target from $6 to $8.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 1:55 pm

ATO

Barclays analyst Eric Beaumont has maintained an Equal-Weight rating on Atmos Energy (NYSE:ATO) but reduced the price target from $116 to $115.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 1:54 pm

RIOT

Cantor Fitzgerald analyst Josh Siegler has reiterated an Overweight rating on Riot Platforms (NASDAQ:RIOT) and maintained a $19 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 1:53 pm

AEP

Barclays analyst Eric Beaumont has maintained an Overweight rating on American Electric Power (AEP) and increased the price target from $82 to $84.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 1:53 pm

AGNC

Barclays analyst Mark Devries has maintained an Equal-Weight rating on AGNC Investment (NASDAQ:AGNC) and increased the price target from $8 to $9.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 1:52 pm

AXSM

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $108.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 1:52 pm

AES

Barclays analyst Stephen Byrd has maintained an Overweight rating on AES Corporation (NYSE:AES) and increased the price target from $18 to $21.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 1:51 pm

BBIO

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on BridgeBio Pharma (NASDAQ:BBIO) and maintained a price target of $50.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 1:47 pm